TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07580716: Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

Sponsor: Enlivex Therapeutics Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 182 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,070,000

Rescue Site Savings

+$1,380,000

Unlock Full NCT07580716 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07580716 Rescue Dossier →